Meeting
2014 Breast Cancer Symposium
The 21-gene breast cancer assay in small (<1cm) tumors.
Authors
Christy Ann Russell
USC Norris Comprehensive Cancer Center, Los Angeles, CA
Christy Ann Russell , Melissa Conrad Stoppler , Megan Rothney , Amy P. Sing
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Risk Assessment, Prevention, Early Detection, Screening, and Systemic Therapy
Track
Systemic Therapy,Risk Assessment, Prevention, Early Detection, and Screening
Sub Track
Genomics
Citation
J Clin Oncol 32, 2014 (suppl 26; abstr 33)
DOI
10.1200/jco.2014.32.26_suppl.33
Abstract #
33
Poster Bd #
C6
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Clinical outcomes in ER+ HER2-negative breast cancer (BC) where treatment decisions incorporated the 21-gene recurrence score (RS): Elderly (≥70 yrs) vs younger patients (Pts).
First Author: Salomon M. Stemmer
Poster
2013 Breast Cancer Symposium
21-gene recurrence score testing and subsequent treatment decisions in patients (pts) with estrogen-receptor–positive (ER+) early-stage breast cancer (ESBC).
First Author: Jennifer B. Manders
Poster
2021 ASCO Annual Meeting
Validation of the RSClin risk calculator using the National Cancer Database (NCDB).
First Author: Frederick Howard
Poster
2020 ASCO Virtual Scientific Program
Real-world analysis of clinical and economic impact of 21-gene recurrence score (RS) testing in early-stage breast cancer (ESBC) in Ireland.
First Author: Lynda M McSorley